[{"data":1,"prerenderedAt":235},["ShallowReactive",2],{"drug-methylnaltrexone":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":21,"regimens":46,"contraindications":113,"warnings":123,"renal":131,"monitoring":141,"interactions":142,"review":143,"examples":146,"atc":166,"iran":168,"links":175,"populations":195,"usApproval":230},"methylnaltrexone",1,{"fa":7,"en":8},"متیل‌نالترکسون","Methylnaltrexone","alimentary-metabolism",{"fa":11,"en":12},"آنتاگونیست محیطی گیرنده اپیوئید (PAMORA)","Peripherally acting opioid antagonist (PAMORA)",[14],{"name":15,"market":16},"Relistor","US",[18,19,20],"relistor","رلیستور","متیل نالترکسون",[22,36],{"id":23,"form":24,"route":25,"label":26,"concentration":27,"markets":31,"refs":32},"tab-150","tablet","oral","150 mg tablet",{"amount":28,"unit":29,"perUnit":24,"scored":30},150,"mg",false,[16],[33],{"source":34,"section":35},"fda-relistor","3",{"id":37,"form":38,"route":39,"label":40,"concentration":41,"markets":43,"refs":44},"pfs-12","injection","sc","12 mg\u002F0.6 mL vial or syringe (8 mg\u002F0.4 mL syringe)",{"amount":42,"unit":29,"perVolumeMl":5},20,[16],[45],{"source":34,"section":35},[47,72,84],{"id":48,"disease":49,"label":50,"population":53,"type":57,"unit":29,"dose":58,"refs":60,"allowedFormulations":63,"notes":64},"cncp-po","opioid-induced-constipation",{"fa":51,"en":52},"یبوست ناشی از اپیوئید در درد مزمن غیرسرطانی — ۴۵۰ mg خوراکی صبح","OIC in chronic non-cancer pain — 450 mg orally each morning",{"minAge":54},{"value":55,"unit":56},18,"year","fixed",{"perDose":59,"dosesPerDay":5},450,[61],{"source":34,"section":62},"2.2",[23],[65],{"text":66,"refs":69},{"fa":67,"en":68},"ملین نگهدارنده پیش از شروع قطع. نزدیک دستشویی باشد. با قطع اپیوئید قطع شود.","Stop maintenance laxatives before starting. Stay near a toilet. Stop when the opioid is stopped.",[70],{"source":34,"section":71},"2.1",{"id":73,"disease":49,"label":74,"population":77,"type":57,"unit":29,"dose":79,"refs":81,"allowedFormulations":83},"cncp-sc",{"fa":75,"en":76},"یبوست ناشی از اپیوئید در درد مزمن غیرسرطانی — ۱۲ mg زیرجلدی روزانه","OIC in chronic non-cancer pain — 12 mg SC daily",{"minAge":78},{"value":55,"unit":56},{"perDose":80,"dosesPerDay":5},12,[82],{"source":34,"section":62},[37],{"id":85,"disease":49,"label":86,"population":89,"type":93,"unit":29,"dose":94,"refs":101,"durationDays":104,"allowedFormulations":105,"notes":106},"adv",{"fa":87,"en":88},"یبوست ناشی از اپیوئید در بیماری پیشرفته — یک روز در میان: ۳۸ تا \u003C۶۲ kg: ۸ mg؛ ۶۲ تا ۱۱۴ kg: ۱۲ mg","OIC in advanced illness — every other day: 38–\u003C62 kg: 8 mg; 62–114 kg: 12 mg",{"minAge":90,"minWeightKg":91,"maxWeightKg":92},{"value":55,"unit":56},38,114,"weightBand",{"weightBands":95},[96,100],{"minWeightKg":97,"maxWeightKg":98,"perDose":99,"dosesPerDay":5},37.99,61.99,8,{"minWeightKg":98,"maxWeightKg":92,"perDose":80,"dosesPerDay":5},[102],{"source":34,"section":103},"2.3, Table 1",{"min":5,"max":5},[37],[107],{"text":108,"refs":111},{"fa":109,"en":110},"زیر ۳۸ یا بالای ۱۱۴ kg: ۰٫۱۵ mg\u002Fkg. بیش از یک دوز در ۲۴ ساعت نه.","\u003C38 or >114 kg: 0.15 mg\u002Fkg. Not more than one dose per 24 h.",[112],{"source":34,"section":103},[114],{"id":115,"severity":116,"text":117,"refs":120},"ci","block",{"fa":118,"en":119},"انسداد گوارشی شناخته یا مشکوک و خطر انسداد مجدد.","Known or suspected GI obstruction and risk of recurrent obstruction.",[121],{"source":34,"section":122},"4",[124],{"text":125,"refs":128},{"fa":126,"en":127},"سوراخ‌شدگی گوارش؛ اسهال یا درد شکمی شدید؛ علائم ترک اپیوئید.","GI perforation; severe diarrhoea or abdominal pain; opioid withdrawal.",[129],{"source":34,"section":130},"5",[132],{"egfrBelow":133,"severity":134,"text":135,"refs":138},60,"warn",{"fa":136,"en":137},"ClCr زیر ۶۰: قرص ۱۵۰ mg؛ تزریق ۶ mg (درد غیرسرطانی)؛ بیماری پیشرفته نصف دوز جدول.","CrCl \u003C60: tablets 150 mg; injection 6 mg (non-cancer pain); advanced illness half the table dose.",[139],{"source":34,"section":140},"2.4",[],[],{"status":144,"reviewer":145,"date":145},"unverified",null,[147,153,157,163],{"regimen":48,"formulation":23,"input":148,"expect":151},{"ageYears":149,"weightKg":150},50,75,{"perDose":59,"tabletsPerDoseRounded":152},3,{"regimen":73,"formulation":37,"input":154,"expect":155},{"ageYears":149,"weightKg":150},{"perDose":80,"mlPerDose":156},0.6,{"regimen":85,"formulation":37,"input":158,"expect":161},{"ageYears":159,"weightKg":160},70,55,{"perDose":99,"mlPerDose":162},0.4,{"regimen":85,"formulation":37,"input":164,"expect":165},{"ageYears":159,"weightKg":150},{"perDose":80,"mlPerDose":156},[167],"A06AH01",{"status":169,"refs":170},"not-found",[171],{"source":172,"section":173,"url":174},"darooyab-generic","G-5289\u002FMethylnaltrexone","https:\u002F\u002Fwww.darooyab.ir\u002FG-5289\u002FMethylnaltrexone",[176,180,184,187,190,193],{"kind":177,"url":178,"label":179},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=208271","NDA208271",{"kind":181,"url":182,"label":183},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=c488fb7c-0a5b-487c-b452-996809d1cb99","FDA Relistor",{"kind":185,"url":186,"label":8},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa616047.html",{"kind":185,"url":188,"label":189},"https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa608052.html","Methylnaltrexone Injection",{"kind":191,"url":192,"label":167},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=A06AH01",{"kind":194,"url":174,"label":8},"darooyab",{"pregnancy":196,"lactation":205,"pediatric":214,"geriatric":222},{"level":197,"text":198,"quote":201,"refs":202},"caution",{"fa":199,"en":200},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Risk Summary The limited available data with RELISTOR in pregnant women are not sufficient to inform a drug-associated risk for major birth defects and miscarriages.",[203],{"source":34,"section":204},"8.1",{"level":206,"text":207,"quote":210,"refs":211},"avoid",{"fa":208,"en":209},"برچسب: شیردهی توصیه نمی‌شود یا باید بین دارو و شیردهی یکی انتخاب شود.","Label: breastfeeding not recommended, or choose between the drug and breastfeeding.","Because of the potential for serious adverse reactions, including opioid withdrawal, in breastfed infants, advise women that breastfeeding is not recommended during treatment with RELISTOR.",[212],{"source":34,"section":213},"8.2",{"level":197,"text":215,"quote":218,"refs":219},{"fa":216,"en":217},"برچسب برای کودکان شرط، محدودیت سنی یا نکته دارد؛ جمله برچسب در زیر آمده است.","The label has conditions, age limits or notes for children; the label sentence is quoted below.","Safety and effectiveness of RELISTOR tablets and injection have not been established in pediatric patients.",[220],{"source":34,"section":221},"8.4",{"level":197,"text":223,"quote":226,"refs":227},{"fa":224,"en":225},"برچسب: در سالمندان با احتیاط و معمولاً از دوز پایین شروع شود.","Label: use with caution in older adults, usually starting at the low end of the dose range.","Monitor elderly patients for adverse reactions.",[228],{"source":34,"section":229},"8.5",{"kind":231,"refs":232,"id":179},"NDA",[233],{"source":34,"section":234},"SPL approval \u002F marketing category",1792444700985]